Acurx Pharmaceuticals (ACXP) Competitors $4.72 +0.17 (+3.74%) Closing price 04:00 PM EasternExtended Trading$4.64 -0.08 (-1.69%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. TPST, MDCX, BDRX, RNTX, NNVC, TENX, JATT, BTAI, FBLG, and MIRAShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Tempest Therapeutics (TPST), Medicus Pharma (MDCX), Biodexa Pharmaceuticals (BDRX), Rein Therapeutics (RNTX), NanoViricides (NNVC), Tenax Therapeutics (TENX), JATT Acquisition (JATT), BioXcel Therapeutics (BTAI), FibroBiologics (FBLG), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Tempest Therapeutics Medicus Pharma Biodexa Pharmaceuticals Rein Therapeutics NanoViricides Tenax Therapeutics JATT Acquisition BioXcel Therapeutics FibroBiologics MIRA Pharmaceuticals Tempest Therapeutics (NASDAQ:TPST) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership. Is TPST or ACXP more profitable? Tempest Therapeutics' return on equity of -334.76% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -334.76% -130.63% Acurx Pharmaceuticals N/A -436.83%-192.25% Do institutionals & insiders hold more shares of TPST or ACXP? 22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, TPST or ACXP? Tempest Therapeutics has a beta of -1.93, indicating that its stock price is 293% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.27, indicating that its stock price is 227% less volatile than the S&P 500. Which has higher valuation & earnings, TPST or ACXP? Tempest Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$41.84M-$14.59-0.69Acurx PharmaceuticalsN/AN/A-$14.10M-$10.69-0.44 Does the media prefer TPST or ACXP? In the previous week, Acurx Pharmaceuticals had 4 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Acurx Pharmaceuticals and 0 mentions for Tempest Therapeutics. Acurx Pharmaceuticals' average media sentiment score of 0.76 beat Tempest Therapeutics' score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Tempest Therapeutics Neutral Acurx Pharmaceuticals Positive Do analysts prefer TPST or ACXP? Tempest Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 199.40%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 556.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAcurx Pharmaceuticals beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.21M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.09%P/E Ratio-0.4420.8831.1026.05Price / SalesN/A355.46459.33116.07Price / CashN/A43.1937.7358.48Price / Book2.108.129.536.61Net Income-$14.10M-$54.72M$3.26B$265.56M7 Day Performance-7.63%2.62%2.11%1.98%1 Month Performance-50.83%7.63%5.12%1.33%1 Year Performance-89.78%13.11%31.25%21.15% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.9183 of 5 stars$4.72+3.7%$31.00+556.8%-90.2%$7.21MN/A-0.443Gap UpTPSTTempest Therapeutics1.2297 of 5 stars$8.01+8.8%$30.00+274.5%-51.4%$27.10MN/A-0.4520MDCXMedicus Pharma1.9406 of 5 stars$1.97flat$23.50+1,092.9%N/A$26.74MN/A-1.70N/ANews CoverageAnalyst ForecastGap DownBDRXBiodexa Pharmaceuticals0.3355 of 5 stars$6.89-3.4%N/AN/A$26.06M$470K0.0020Gap DownRNTXRein TherapeuticsN/A$1.16+4.5%N/AN/A$25.58MN/A-0.419News CoverageAnalyst DowngradeNNVCNanoViricides0.759 of 5 stars$1.54-2.5%N/A-32.3%$24.75MN/A-2.1420TENXTenax Therapeutics1.6686 of 5 stars$5.85-1.0%$17.50+199.1%+43.1%$24.52MN/A-2.369JATTJATT AcquisitionN/A$1.42-4.1%N/A-50.7%$24.50MN/A0.003Gap UpHigh Trading VolumeBTAIBioXcel Therapeutics4.582 of 5 stars$6.40+58.4%$49.25+669.5%-52.0%$24.47M$2.27M-0.4790Short Interest ↓Gap DownHigh Trading VolumeFBLGFibroBiologics2.7759 of 5 stars$0.55-4.8%$13.00+2,243.6%-62.7%$24.40MN/A-1.5410Short Interest ↑MIRAMIRA Pharmaceuticals3.0737 of 5 stars$1.42+2.9%$17.00+1,097.2%-29.3%$23.35MN/A-2.782 Related Companies and Tools Related Companies Tempest Therapeutics Alternatives Medicus Pharma Alternatives Biodexa Pharmaceuticals Alternatives Rein Therapeutics Alternatives NanoViricides Alternatives Tenax Therapeutics Alternatives JATT Acquisition Alternatives BioXcel Therapeutics Alternatives FibroBiologics Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access